The US government approved a medical device that was highly sought after by military officials to stem battlefield bleeding and save limbs, despite internal warnings among regulators that the product poses serious risks that could lead to death, a former US Food and Drug Administration reviewer said.
Robert Lee, who spent 10 years at the FDA, said agency reviewers were pressured to approve Humacyte Inc.’s Symvess even after he says he repeatedly raised concerns with senior FDA leadership and asked them to hold a public advisory panel meeting of outside experts to discuss the risks and benefits of the product.
“This thing has ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.